Form 4: Akero Therapeutics Chief Development Officer Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Development Officer, Catriona Yale, sold 2,810 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Catriona Yale, Chief Development Officer of Akero Therapeutics, sold 2,810 shares of common stock on December 10, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $30.79, with individual transactions ranging from $30.74 to $30.83.
• Following the transaction, Ms. Yale directly owns 71,348 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event, reflecting a routine transaction for tax purposes. It does not indicate a change in the company's fundamentals or the executive's outlook.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• The sale of shares to cover tax obligations is a standard practice among publicly traded companies.
• Many companies have 'sell-to-cover' policies to manage these transactions automatically.
• This type of transaction is common for executives at companies like Amgen, Gilead, and Regeneron, which also use stock-based compensation.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Akero Therapeutics, insider trading, stock sale, Form 4, Catriona Yale, executive compensation, tax obligations, restricted stock units